to tocilizumab naïve and have at least one six monthly study follow-up recorded after starting tocilizumab. Baseline characteristics at point of starting tocilizumab are described. Linear regression, fully adjusted for relevant confounders, was used to investigate the relationship between change in DAS28 score from baseline to six months and body weight per ten kilograms (kg), and in a separate analysis, as BMI category. Multiple imputation was used to handle missing data.

**Results:** 1241 patients starting tocilizumab (902 IV, 339 SC) were eligible for analysis. The median age was 59 years, majority were female, and had median disease duration of 11 years at baseline. Over seventy percent had prior biologic exposure. Median weight was 77kg for IV and 76kg for SC starters, and the majority of patients were categorised as normal weight (30% IV, 37% SC) or pre-obesity (31% IV & SC) according to BMI. Median DAS28 score was 5.8 (IV) and 5.5 (SC) at start of treatment with median improvement after 6-months of 1.50 and 2.02 units respectively. The fully adjusted linear regression model showed no association between body weight or BMI and change in DAS28 score at six months for patients starting IV or SC tocilizumab (Table).

**Table**

<table>
<thead>
<tr>
<th>Baseline Variable</th>
<th>Intravenous TCZ patients (n=902)</th>
<th>Subcutaneous TCZ patients (n=339)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR)</td>
<td>58 (50-67)</td>
<td>60 (51-70)</td>
</tr>
<tr>
<td>Gender, n (%) female</td>
<td>708 (78)</td>
<td>233 (74)</td>
</tr>
<tr>
<td>Disease duration, median (IQR)</td>
<td>11 (4-21)</td>
<td>11 (4-21)</td>
</tr>
<tr>
<td>DAS28 score, median (IQR)</td>
<td>5.8 (5.1-6.6)</td>
<td>5.5 (4.7-6.5)</td>
</tr>
<tr>
<td>Change in DAS28 score, median (IQR)</td>
<td>-1.50 (-1.0 -0.23)</td>
<td>-2.02 (-2.3 -2.07)</td>
</tr>
<tr>
<td>Weight in Kgs, median (IQR)</td>
<td>77 (64-91)</td>
<td>76 (64-88)</td>
</tr>
</tbody>
</table>

*Fully adjusted for age, gender, disease duration, baseline DAS28 score, baseline HAQ score, co-morbidities, and number of previous biologics*

**Conclusion:** Data from this study show that body weight does not appear to affect initial response to IV or SC tocilizumab. This is reassuring given that patients are likely to be given SC tocilizumab due to ease of administration and reduced hospital costs.

**Disclosure of Interests:** Rebecca Davies: None declared, Arani Vivekanantham: None declared, Mark Lunt: None declared, Kath Watson: None declared, Kimme Hyrich Grant/research support from: Pfizer, UCB, BMS, Speakers bureau: Abbvie, James Bluett: None declared

**DOI:** 10.1136/annrheumdis-2020-eular.4164

---

**SAT0104**

**MAINTENANCE OF SDAI REMISSION AND PATIENT-REPORTED OUTCOMES (PROS) FOLLOWING DOSE DE-ESCALATION OF ABATACEPT IN MTX-NAIVE, ANTICITRULLINATED PROTEIN ANTIBODY (ACPA)+ PATIENTS WITH EARLY RA: RESULTS FROM AVERT-2, A RANDOMISED PHASE IIIB STUDY

**P. Emery**1, Y. Tanaka2, V. Bykerk2, H. Huizinga4, C. Citera2, B. Bingham2, J. Breezewicz2, J. Connolly5, J. Zhuo2, R. Wong2, K. H. G. Hwang5, K. Lozenzki6, Y. Elbeiz7, F. Fleischmann8,9, LIRMM, University of Leeds, NIHR BRC LHT, Leeds, United Kingdom; 1University of Occupational and Environmental Health, Kitakyushu City, Japan; 2Hospital for Special Surgery, New York, United States of America; 3Leiden University Medical Center, Leiden, Netherlands; 4Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina; 5Johns Hopkins University, Baltimore, United States of America; 6Bristol-Myers Squibb, Princeton, United States of America; 7Ecole de Boulogne-Billancourt, France; 8University of Texas, Dallas, United States of America

**Background:** The Phase IIb Assessing Very Early RA Treatment (AVERT)-2 trial (NCT02504268) evaluated SC abatacept (ABA) + MTX vs ABA placebo (PBO) + MTX in ACPA+ patients (pts) with early, active RA.1 Results from the 56-wk induction period (IP) showed a significantly greater proportion of pts treated with ABA + MTX (vs MTX alone) reported clinically meaningful improvements in HAQ-DI, global disease activity and pain, which were sustained at 52 wks.2

**Objectives:** To report maintenance of SDAI remission and PROs from the AVERT-2 de-escalation (D-E) period.

**SAT0103**

**THE EFFECT OF BODYWEIGHT ON RESPONSE TO INTRAVENOUS OR SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS

**R. Davies**1, A. Vivekanantham2, M. Lunt3, K. Watson5, K. Hyrich1,2, J. Bluett3,4 on behalf of BSRB-RA Contributors Group. 1University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 2University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 3Manchester Academic Health Science, National Institute of Health Research Musculoskeletal Biomedical Research Centre, Manchester, United Kingdom; 4University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 5University of Manchester, Versus Arthritis Centre for Genetics and Genomics, Manchester, United Kingdom

**Background:** Tocilizumab is an IL-6 receptor humanised monoclonal antibody treatment option in rheumatoid arthritis (RA) who have not responded or are intolerant of disease modifying anti-rheumatic drugs (DMARDs) or other biologics. Tocilizumab was available initially as an intravenous (IV) preparation, dosed according to weight, and more recently as a subcutaneous (SC) preparation given at 162mg weekly irrespective of body weight. Obesity is highly prevalent in RA and there has been concern that starting or switching patients to SC tocilizumab could reduce its effectiveness in those patients with a higher body weight when compared to IV tocilizumab.

**Objectives:** To investigate the relationship between bodyweight and DAS28 response at 6 months in tocilizumab naïve RA patients starting IV or SC tocilizumab.

**Methods:** The study population comprised RA subjects recruited to the BSRB-RA until March 30/11/2018 commencing IV or SC tocilizumab for the first time. Patients had